FRANKFURT Sept 5 (Reuters) - BioNTech and its

partner Duality Biologics said on Friday that a

late-stage trial testing their precision drug against a certain

type of breast cancer reached its main goal of slowing down

disease progression.

For COVID-19 vaccine maker BioNTech, the news marks the

first success in a cancer trial that could potentially lead to

market approval amid a renewed focus on its traditional roots in

oncology.

In a joint statement, the partners said that a Phase 3 trial

testing experimental drug BNT323 in China in comparison with

Roche's Kadcyla in certain cases of breast cancer met

the primary endpoint of progression-free survival at a

pre-specified interim analysis.